Personalized Cancer Vaccine Summit
Evvnt Promotion / evvnt
Archiv
03.12.2024 - 05.12.2024 Hilton Boston Back Bay, 40 Dalton Street, 02115 Boston, Massachusetts, USA
Time: 8:00 AM - 5:00 PM
Kongressthemen
With recent advancements into Phase II and III trials for personalized cancer vaccines along with 437 other candidates in development, the biopharma industry is at a critical point to demonstrate safe and efficacious results that will offer a real hope for every patient with a cure for cancer.
With recent advancements into Phase II and III trials for personalized cancer vaccines along with 437 other candidates in development, the biopharma industry is at a critical point to demonstrate safe and efficacious results that will offer a real hope for every patient with a cure for cancer.
Kongressorganizer (PCO)
Hanson Wade
Hanson Wade
Anmerkungen
URL:
Brochure: https://go.evvnt.com/2558274-3?pid=4832
Speakers: Agnete Fredriksen, Chief Scientific Officer, Nykode Therapeutics, Charles Link, Chief Medical Officer, Syncromune, David Berd, Chief Medical Officer, Biovaxys, and more
URL:
Brochure: https://go.evvnt.com/2558274-3?pid=4832
Speakers: Agnete Fredriksen, Chief Scientific Officer, Nykode Therapeutics, Charles Link, Chief Medical Officer, Syncromune, David Berd, Chief Medical Officer, Biovaxys, and more
Anfragen und Anmeldung:
https://go.evvnt.com/2558274-2?pid=4832
Frau Isabel Weir
Onkologie
Sprache
Englisch
Englisch
Kongressgebühr
USD 2599.00 - USD 5097.00
USD 2599.00 - USD 5097.00
Teilnehmer erwartet
1000 - 1000
1000 - 1000
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
83 Great Titchfield Street
W1W 6RH London
Großbritannien
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."
